Even as Gilead looks to become an oncology powerhouse in the coming years, the company on Monday recorded a major setback for its antibody-drug conjugate (ADC) Trodelvy.The company’s phase 3 EVOKE-1 trial showed that Trodelvy didn’t significantly extend the lives of patients with previously treated metastatic non-small cell lung cancer (NSCLC) when pitted against the […]
